MRL Ventures Fund
Corporate VCCambridge · Pre-Seed–Series B · 8 people tracked
Find your way into MRL Ventures Fund
2,113 people in our graph share verified history with the MRL Ventures Fund team — schools, employers, funds. One of them is your warm intro.
Investment thesis
MRLV is a science-first corporate venture fund investing in early-stage, preclinical therapeutics companies pursuing first- and best-in-class innovation with the potential to transform standards of care. It evaluates opportunities on the strength of underlying biology, quality of translational data, a clear path to human proof-of-concept, and the team's capabilities and syndicate alignment. MRLV focuses exclusively on therapeutics across all modalities — from small molecules to cell therapies — and explicitly excludes medical devices, diagnostics and digital health. It typically leads or co-leads with up to $25M per company from concept to IND, taking board or observer roles and offering access to MSD's scientific and business-development expertise without requiring product or technology rights.
Source: firm website, verified Aug 7, 2026.
Team · 8 people
from the firm's website & curated & public directories
What they invest in
from 28 of 40 portfolio companiesBiotech ×28Healthtech ×18Medical Devices ×12AI & Machine Learning ×6Deep Tech ×5Digital Health ×2Longevity ×2
HQs:United States×18Australia×1Belgium×1
Who they back
founder profiles across 15 portfolio companiesFounding team size:solo founder×102 founders×33 founders×2
Where their founders studiedfrom 13 founders with education data
Harvard Business School ×2
What their founders studiedfrom 12 founders with field-of-study data
Life Sciences ×5Chemistry ×3Business & Management ×2Medicine ×2
Where their founders worked beforefrom 12 founders with career history
MPM BioImpact ×2
Investments · 40 tracked
founders shown can be your intro pathBy year:2026 · 12025 · 12024 · 32023 · 22020 · 32015 · 111 dated
Aktis Oncology discovers and develops targeted radiopharmaceuticals for treating solid tumors.
BiotechHealthtechMedical DevicesBoston, US
Todd Foley(Co-founder and Chairman)inPatrick Baeuerle(Co-founder & Advisor)inShulamit Ron-Bigger(Executive Officer)inKyle D. Kuvalanka(Chief Financial Officer)inAkos Czibere(Chief Medical Officer)inPaul L. Feldman(Chief Scientific Officer)in
Co-investorsAndreessen HorowitzEcoR1 CapitalMPM BioImpactRA CapitalTCG CrossoverVida Ventures+4 more
Alector develops therapies targeting neurodegenerative diseases including Alzheimer's, frontotemporal dementia, and Parkinson's disease through protein removal, replacement, and immune cell restoration.
AI & Machine LearningBiotechHealthtechLongevityMedical DevicesSan Francisco, US
Arnon Rosenthal(Ph.D.)inTillman Gerngross(Director)Arnon Rosenthal PhD(Founder)in
BoardCarl Gordon(Director)Terry McGuire(Director)in
Co-investorsForesite CapitalMission Bay CapitalMission BiocapitalSV Health InvestorsPolaris Partners
Entrada Therapeutics is a biotech company developing intracellular therapeutics based on its proprietary EEV Platform, aimed at reaching previously inaccessible or undruggable disease-causing targets inside cells.
BiotechHealthtechBoston, US
Natarajan Sethuraman(Executive Officer)inNerissa Kreher(Executive Officer)inKory Wentworth(Executive Officer)inDipal Doshi(Chief Executive Officer)inNathan Dowden(Executive Officer)inNatarajan Sethuraman, PhD(President of Research and Development)
Co-investors5AM VenturesAgent CapitalMPM BioImpactRoche Venture FundTCG Crossover
Invivyd develops monoclonal antibody medicines for the prevention and treatment of serious viral infectious diseases, starting with COVID-19 and other high-need indications.
BiotechHealthtech
Co-investorsBain Capital Life SciencesForesite CapitalPremji InvestGV (Google Ventures)MITHRILMithril Capital Management+2 more
Kymera is a clinical-stage biotechnology company developing novel medicines using targeted protein degradation technology to treat diseases caused by previously "undrugged" proteins.
BiotechDeep TechHealthtech
Nello Mainolfi(Founder)inBruce Booth(Chair)in
Co-investorsAtlas VentureAvoro Capital AdvisorsBain Capital Life SciencesBessemer Venture PartnersHatteras Venture PartnersNextech Invest+5 more
Spero Therapeutics is a clinical-stage biopharmaceutical company developing medicines for immune-mediated diseases, led by SP001, a third-generation anti-CD40L antibody targeting IgG4-related disease.
BiotechCambridge, US
Ankit Mahadevia(Executive Officer, Director)inStephen Garbacz(Executive Officer)inEsther Rajavelu(Director, President, Chief Executive Officer, Chief Financial Officer, Chief Business Officer and Treasurer)in
BoardJean-Francois Formela(Director)inReza Halse(Director)Casper Breum(Director)
Co-investorsHEALTHCARE ROYALTY PARTNERSOUP (Osage University Partners)RA CapitalAlphabetAtlas VentureFidelity Investments
Xilio Therapeutics is a clinical-stage biotechnology company developing masked immuno-oncology therapies that use protein engineering to remain inactive until activated by tumor-specific proteases within the tumor microenvironment.
BiotechHealthtechWaltham, US
René Russo(Executive Officer, Director)inJoseph Farmer(Executive Officer)Timothy Clackson(Executive Officer)Christopher Frankenfield(Chief Financial and Operating Officer)inKatarina Luptakova(Chief Medical Officer)inPaul Clancy(Director)
Co-investorsBain Capital Life SciencesBay City CapitalF-Prime CapitalM VenturesRA CapitalRiverVest Venture Partners+8 more
ATB Therapeutics is a biotech company developing bispecific antibody therapies and related immunological treatments.
BiotechHealthtechMedical Devices
Dr. Mark Throsby(Chief Executive Officer)
Co-investorsV-Bio VenturesVIVES PartnersEQT Life SciencesSambrinvestWallonie Entreprendre
Axonis Therapeutics is a biotechnology company developing small-molecule medicines that target KCC2, a mediator of inhibition in the brain, to treat neurological disorders such as epilepsy and pain.
BiotechDeep TechBoston, US
Shane V. Hegarty(Chief Scientific Officer & Co-Founder)inJoanna Stanicka(Chief Executive Officer, President & Co-Founder)inJeff Imbaro(Chief Operating Officer)inTiasha Shafiq(Chief of Staff)in
BoardCorey . Goodman(Director)inJonathan Leff(Director)in
Co-investorsvenBio PartnersSofinnova VenturesCivilization Ventures Management, LlcCreative Destruction Lab (CDL)Hatteras Venture PartnersIaso Ventures+7 more
InduPro develops next-generation protein therapeutics by leveraging inherent and induced proximity to modulate disease biology, with a focus on ADCs and T-cell engagers.
BiotechDeep TechMedical DevicesSeattle, US
K. Chris Garcia(Scientific Founder)Prakash Raman(CEO)inAmanda J. Redig(Chief Medical Officer)inScott Lesley(President & CSO)inPamela Holland(SVP of Biology)inSally Johnson(Chief People Officer)in
Co-investorsThe Column GroupVida Ventures
Photys Therapeutics develops bifunctional small-molecule medicines that use induced proximity to recruit kinases and drive targeted protein phosphorylation, aiming to modulate and repair disease-driving proteins.
BiotechHealthtechLongevityWaltham, US
Amit Choudhary(Scientific Founder)David Steinberg(Chairman & Founding CEO)inEdward Holson(Co-founder & CSO)inLizzie Ngo(Co-founder)inBrian Fenton(President & CEO)in
Co-investorsLongwood FundMPM BioImpact8VCOno Venture Investment, Inc.
Therini Bio is a biotechnology company developing fibrin-targeting therapeutics to treat neurological and ophthalmological diseases, leveraging scientific discoveries in neurovascular and neuroimmune mechanisms of disease.
BiotechDigital HealthHealthtechMedical DevicesSacramento, US
Katerina Akassoglou(Scientific Founder, Director of the Center for Neurovascular Brain Immunology and Professor of Neurology at UCSF and Gladstone Institutes)inKaterina Akassoglou, PhD(Scientific Founder)Leslie Schulze(Executive Officer)Tara Nickerson(Executive Officer, Director)in
)
BoardOlga Danilchanka(Director)inLaia Crespo-Martin(Director)
Co-investorsSanofi VenturesSV Health InvestorsAngelini VenturesMitsui Global InvestmentApollo Health VenturesDementia Discovery Fund+1 more
Topo Therapeutics is a drug discovery company developing treatments targeting ion channels and transmembrane proteins for conditions such as pain, epilepsy, and CNS, pulmonary, and renal diseases.
BiotechHealthtechCambridge, US
Hui Tian(Executive Officer, Director)inMadgalene Moran(Executive Officer, Director)Magdalene Moran(Chief Executive Officer)
BoardBruce Bean(Director)James Jeffrey Goater, Jr.(Director)
Board seatKarin Kleinhans· per SEC Form D · $95M raise · filed Dec 2024
Co-investorsSR One Capital ManagementThe Column Group
Ambagon develops small molecule stabilizers of 14-3-3 protein complexes to modulate disease-related protein interactions, targeting therapeutic areas including cancer, metabolic disorders, neurodegenerative and infectious diseases.
BiotechDeep TechMedical DevicesEindhoven, US
Christian Ottmann(Executive Officer)inJosh Seidenfeld(Executive Officer)Michelle Arkin(Director)Nancy Pryer(Executive Officer)Margarita Chavez(Director)Bryan Miller(Executive Officer)
Co-investorsDroia VenturesMission BiocapitalNextech InvestInkefRA Capital
Caraway Therapeutics was a preclinical biopharmaceutical company developing small-molecule therapies modulating lysosomal function to treat neurodegenerative and rare diseases.
BiotechHealthtech
Co-investorsEisai Innovation, Inc.SV Health Investors
CAR-Macrophage cellular therapeutics with initial oncology focus (NASDAQ: CARM).
BiotechPhiladelphia, US
Steven Kelly(Executive Officer, Director)in
BoardMargarita Chavez(Director)inEran Nadav(Director)Althea Stillman(Director)Jacob Gunterberg(Director)Regina Hodits(Director)in
Co-investorsAgent CapitalAju IB Invesment CorporationAnzu PartnersGrazia Equity GmbHHealthCapSolasta Ventures+1 more
HotSpot Therapeutics develops novel biopharmaceutical products and therapeutic platforms focused on innovative biomedical technologies.
AI & Machine LearningBiotechHealthtech
BoardBruce Booth(Chairman)in
Co-investorsAtlas VentureB Capital GroupB4 CapitalSofinnova PartnersSolasta VenturesSR One Capital Management
.jpeg){kind=logo}
A pharmaceutical company that develops medicines and vaccines, with research pipelines and clinical trials aimed at new treatments.
BiotechHealthtech
Co-investorsHighlight CapitalAmgen VenturesBlackRockBlackstone Life SciencesClarus VenturesFrazier Healthcare Partners+4 more
Insamo develops an automated platform for drug discovery that designs, synthesizes, and tests cyclic peptides at scale using machine learning and proprietary experimental data.
AI & Machine LearningBiotechDeep TechChippendale, AU
Tim Craven(CEO)inToby Passioura(CSO)inGlen McIntyre(COO)
BoardCOREY GOODMAN(Director)inMATT HERSHENSON(Director)in
Co-investorsCivilization Ventures Management, LlcPlayground GlobalvenBio PartnersAxial VCvenBio Global Strategic
LAVA develops the Gammabody platform, which generates bispecific antibodies that activate gamma-delta T cells to treat cancer by directing immune cells to tumors and triggering anti-cancer immune responses.
AI & Machine LearningBiotechHealthtechMedical Devices
Ton AdanginHans van der Vliet(Head of Innovation)inSteve Hurly(Chief Executive Officer)Oxana Polyakova(Chief Scientific Officer)in
Co-investorsSanofi VenturesYsios CapitalGilde HealthcareREDMILE
Mozart Therapeutics develops protein therapeutics focused on immunology and oncology treatments.
BiotechMedical Devices
Mark Davis(Scientific Co-Founder)K. Christopher Garcia(Scientific Co-Founder)Calvin Kuo(Scientific Co-Founder)Katie Fanning(President & Chief Executive Officer)in
Co-investorsARCH Venture PartnersJDRF T1D FundOno Venture Investment, Inc.Pfizer Venture InvestmentsSofinnova PartnersAlexandria+3 more
Tallac Therapeutics is a clinical-stage biopharmaceutical company developing oligonucleotide-based antibody conjugates (TRAAC candidates) designed to deliver immune-activating agents to tumor microenvironments for oncology indications.
BiotechHealthtechMedical DevicesBurlingame, US
Hong Wan(Executive Officer, Director)in
BoardRan Geng(Director)Michael Carusi(Director)Isaac Cheng(Director)Christine Brennan(Director)Corey Goodman(Director)in
Co-investorsLightstone VenturesvenBio PartnersMatrix Partners ChinavenBio Global Strategic
Sanofi is an R&D-driven, AI-powered biopharmaceutical company that develops medicines and vaccines, with a focus on immunology and the immune system.
AI & Machine LearningBiotechHealthtech
Co-investorsNew Enterprise Associates (NEA)Rho VenturesSanofi VenturesFJ Labs
Viridian Therapeutics develops treatments for thyroid eye disease, a rare autoimmune condition affecting the eyes and orbit.
BiotechDigital HealthMedical DevicesWaltham, US
Jonathan Violin(Executive Officer, Director)in
BoardPeter Harwin(Director)Tomas Kiselak(Director)
Co-investorsBroadview VenturesLongitude Capital
A biologics center of excellence focused on developing and delivering medicines to patients, operating as a subsidiary within the Otsuka pharmaceutical group.
AI & Machine LearningBiotechHealthtechMedical Devices
Zachary Shriver(President and Chief Executive Officer)Karthik Viswanathan(Vice President, Research)in
Co-investorsCTI Life Sciences Fund L.P.Cycad Group LLCLux Capital
Other
Tracked investments with no reachable website or further public details — typically companies that wound down, renamed, or were absorbed.
ADRxAnavo TherapeuticsAxonisEyeBioGlobal Health Innovation FundImago BiosciencesLifeMineMyoventivePhotysRay TherapeuticsTopoTranslate BioVectorY Therapeutics
Rows marked “SEC filing” are inferred from directors named on the company's SEC Form D — public regulatory data, not a portfolio list published by the firm.
Exits · 13
7 IPOs · 6 acquisitionsAktis OncologyNASDAQ: AKTSAlectorNASDAQ: ALECEntrada Therapeutics, Inc.NASDAQ: TRDAInvivydNASDAQ: IVVDKymera TherapeuticsNASDAQ: KYMRSpero TherapeuticsNASDAQ: SPROXilio TherapeuticsNASDAQ: XLOCarawayacq. by MerckEyeBioacq. by MerckImago Biosciencesacq. by MerckTidal Therapeuticsacq. by SanofiTranslate Bioacq. by SanofiVISTERRA, INC.acq. by Otsuka
Portfolio news
latest coverage across their companiesViridian Therapeutics · investing.com · Sep 8, 2026
Invivyd · investors.invivyd.com · Sep 1, 2026
Spero Therapeutics · marketbeat.com · Aug 18, 2026
Xilio Therapeutics · tickerreport.com · Aug 15, 2026
Alector · dailypolitical.com · Jul 17, 2026
Therini Bio · ophthalmologytimes.com · May 21, 2026
Ray Therapeutics · finsmes.com · Apr 21, 2026
IPO stake values · per SEC filings · 4
Value of this firm's stake in each portfolio company at its IPO price, from the prospectus principal-stockholder table.
| Company | Owned | IPO price | At IPO | Stake value |
|---|---|---|---|---|
| Alector | 4.6% | $25.00 | Jan 2020 | $88.6M |
| Entrada Therapeutics, Inc. | 5.8% | $20.00 | Nov 2021 | $34.8M |
| Xilio Therapeutics | 3.7% | $16.00 | Oct 2021 | $15.7M |
| Spero Therapeutics | 5.2% | $12.50 | Jul 2018 | $11.7M |
Source: SEC S-1 / 424B prospectus filings. Stake value = shares beneficially owned × the initial public offering price, as disclosed — a market value at IPO, not a return multiple (the firm's original cost is not disclosed).
Frequently asked questions
- How many investments has MRL Ventures Fund made?
- MRL Ventures Fund has 40 tracked investments, 13 of which have exited, including 5 dated in the last 24 months.
- What stage does MRL Ventures Fund invest at?
- MRL Ventures Fund invests at the Pre-Seed, Seed, Series A, Series B stages.
- What is MRL Ventures Fund's typical check size?
- MRL Ventures Fund typically writes checks of $25M.
- What sectors does MRL Ventures Fund focus on?
- MRL Ventures Fund focuses on Biotech, Healthtech, Medical Devices.
- Where is MRL Ventures Fund located?
- MRL Ventures Fund is headquartered in Cambridge, US.
- Does MRL Ventures Fund lead rounds?
- Yes, MRL Ventures Fund leads investment rounds.
- Who does MRL Ventures Fund co-invest with?
- MRL Ventures Fund most often shares deals with SV Health Investors, Bain Capital Life Sciences, RA Capital, among 58 tracked co-investors.
Co-investors · 2
RA Capital is a multi-stage investment firm focused on healthcare, life sciences, and planetary health, investing across public and private markets and creating new companies through its Raven incubation platform.
MPM BioImpact combines 30+ years of biotech venture capital expertise with impact investing and public market experience, managing early-stage venture funds, private/public impact funds, and a public equities fund focused on transforming patient outcomes.
Firms observed investing alongside MRL Ventures Fund, from public investor directories. Shared companies are the overlap with MRL Ventures Fund's recorded portfolio.
Similar investors
Amadeus Capital Partners is a technology investment firm that backs founders building complex, science-led and deep tech businesses, supporting them over the long term as they scale internationally.
B Capital is a global investment firm backing early to late-stage technology innovators across technology, healthcare, and energy & resilience sectors.
Breyer Capital is a venture capital firm that backs high-impact entrepreneurs, making strategic investments guided by founder passion and its network of experienced investors.
DCVC (Data Collective) is a deep tech venture capital firm that backs entrepreneurs using computational approaches to solve large-scale real-world problems across many industries.
Innovestor is a Finnish investment manager active in venture capital, real estate, and energy storage, and also provides corporate venturing services.